{
    "2021-08-29": [
        [
            {
                "time": "",
                "original_text": "国信证券维持华大基因买入评级，2021年半年报点评：新冠检测持续，加大研发创新",
                "features": {
                    "keywords": [
                        "华大基因",
                        "买入评级",
                        "2021年半年报",
                        "新冠检测",
                        "加大研发",
                        "创新"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "华大基因(300676)：新冠检测持续 加大研发创新",
                "features": {
                    "keywords": [
                        "华大基因",
                        "新冠检测",
                        "加大研发",
                        "创新"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}